Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Cannabis Retail Impact topic
No spam. Unsubscribe anytime.
WSIPP finds nearby cannabis retail linked to higher Medicaid diagnoses and hospitalizations
Summary
A WSIPP report to the LCB using Medicaid claims (2012–2023) found that neighborhoods with retail cannabis access saw a 13% relative rise in underage cannabis‑use‑disorder diagnoses and a 7% rise among legal‑age Medicaid enrollees after retailers opened; inpatient treatment claims rose ~24% in nearby neighborhoods.
A Washington State Institute for Public Policy presentation to the Liquor and Cannabis Board described statistically significant associations between retail cannabis availability and several Medicaid health‑care outcomes. Senior research associate Amani Rishad said the study used 2012–2023 Medicaid claims, compared census tracts with a retailer within a 10‑minute drive to those without, and separated analyses for ages 12–20 and 21–64.
Rishad summarized key model results: “among the underage population … those with retail access are diagnosed with cannabis use disorder a predicted 1.8 percent of the time” versus 1.6 percent without nearby retail — a roughly 13 percent relative difference. For the legal‑age Medicaid population the model estimated about a 7 percent relative increase, which Rishad translated to roughly 12,000 additional claims annually. She also reported that cannabis‑related hospitalizations were about 7 percent higher and inpatient substance‑use treatment related to cannabis was about 24 percent higher in neighborhoods after retailers opened.
Rishad described an event‑study design showing no pre‑existing differences between treatment and comparison tracts in the years before openings; differences emerge about two years after openings, lending support to the view that the increases follow retailer entry rather than precede it. She cautioned that outcomes in claims data are relatively rare and that the analysis pertains only to Medicaid enrollees (about 23% of Washington’s population) and cannot identify the specific products, frequency of use, or direct behavioral causes behind diagnoses.
Asked about next steps, Rishad said WSIPP published the report at the end of September, notifies relevant legislative committees, and presents its findings to committees upon invitation; she has already briefed a work session of the Consumer Protection and Business Committee. WSIPP plans future work on public‑safety outcomes, child welfare and workplace safety, and economic effects of the retail market.
